Ligand Pharmaceuticals Incorporated / Fundamentals
Income statement
- Net revenue
€160.00M - Cost of goods sold
€49.80M - Gross profit
€71.53M - SG&A expenses
€75.96M - R&D expenses
€56.94M - EBITDA
-€60.62M - D&A
-€8.24M - EBIT
-€29.23M - Interest expenses
€243.94K - EBT
-€72.07M - Tax expenses
€4.40M - Net income
-€53.83M
Cash flow statement
- Net deferred tax
€955.31K - Non-cash items
€43.99M - Changes in working capital
-€5.80M - Operating cash flow
€47.30M - Capex
-€2.08M - Other investing cash flow
-€36.44M - Net investing cash flow
-€77.54M - Total cash dividends paid
€0.00 - Issuance of common stock
-€14.17M - Debt repayment
€1.71K - Other financing cash flow
€11.38M - Net financing cash flow
-€9.83M - Foreign exchange effects
€521.15K - Net change in cash
€34.84M - Cash at end of period
€57.72M - Free cash flow
€45.22M
Balance sheet
- Cash and cash equivalents
€57.72M - Cash and short-term investments
€208.99M - Total receivables
€35.22M - Inventory
€13.21M - Other current assets
€43.63M - Total current assets
€301.04M - Property, plant & equipment
€9.91M - Goodwill
€86.61M - Intangible assets
€213.35M - Long-term investments
€9.30M - Other non-current assets
€188.18M - Total non-current assets
€508.07M - Total assets
€809.11M - Accounts payable
€7.32M - Short-term debt
€949.33K - Other current liabilities
€46.59M - Total current liabilities
€55.21M - Long-term debt
€3.95M - Deferred tax liabilities
€27.50M - Other non-current liabilities
€15.75M - Total non-current liabilities
€47.20M - Total liabilities
€102.42M - Common stock
€17.06K - Retained earnings
€393.53M - Other equity
€7.24M - Total equity
€706.69M - Total liabilities and shareholders' equity
€809.11M
Company information
- Market capitalization
€757.02K - Employees
68 - Enterprise Value
€2.14B
Company ratios
- Gross margin
-
44.7% Much better than peer group: -57,659,227,568,961.8% - EBITDA margin
-
-37.9% Much better than peer group: -317,049,075,996,752.5% - EBIT margin
-
-18.3% Much better than peer group: -320,008,859,831,869.6% - EBT margin
-
-45.0% Much better than peer group: -319,629,112,445,719.4% - Net margin
-
-33.6% Much better than peer group: -319,629,112,446,085.5% - ROE
-
-7.6% Much better than peer group: -30.3% - ROA
-
-6.7% Much better than peer group: -40.3% - Asset turnover
-
19.8% Better than peer group: 8.7% - FCF margin
-
30.9% Much better than peer group: -266,321,017,421,358.1% - FCF yield
6,522.7% - Efficiency ratio
137.9% - Net sales per employee
-
€2.35M - Net income per employee
-
-€791.64K